Gilead Sciences Acquires XinThera

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

February 12, 2024

Biotechnology

Gilead Sciences has completed the acquisition of CymaBay Therapeutics for approximately $4.3 billion, paying $32.50 per share in cash. The deal adds CymaBay's investigational PPARδ agonist seladelpar for primary biliary cholangitis (PBC) to Gilead's liver-disease portfolio and is expected to accelerate development and potential commercialization of the therapy.

Gilead Sciences Acquires MiroBio

September 20, 2022

Biotechnology

Gilead Sciences completed the acquisition of U.K.-based biotechnology company MiroBio for approximately $405 million in cash. The deal gives Gilead MiroBio's discovery platform and portfolio of immune inhibitory receptor agonists, including lead investigational antibody MB272, which is in Phase 1 clinical trials.

XenoTherapeutics / Xeno Acquisition Corp Acquire Repare Therapeutics

January 28, 2026

Biotechnology

Repare Therapeutics has been acquired by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly “Xeno”) pursuant to a statutory plan of arrangement. Under the transaction, Repare shareholders received approximately US$2.20 per share plus one contingent value right (CVR) per share; the deal was approved by shareholders and the Superior Court of Québec and will result in Repare’s delisting and suspension of public reporting.

GlaxoSmithKline Acquires Sierra Oncology for $1.9bn

April 13, 2022

Biotechnology

GlaxoSmithKline plc (GSK) has agreed to acquire late-stage biopharmaceutical company Sierra Oncology for $55 per share in cash, representing an approximate equity value of $1.9 billion. The acquisition, expected to close in Q3 2022 subject to customary approvals, brings momelotinib — a late-stage JAK/ACVR1 inhibitor with demonstrated benefit on symptoms, splenic response and anaemia in myelofibrosis — into GSK's haematology portfolio to strengthen its specialty medicines capability and global commercial reach.

Pharmacosmos Acquires G1 Therapeutics

August 7, 2024

Biotechnology

Pharmacosmos A/S, through its U.S. affiliate Pharmacosmos Therapeutics Inc., agreed to acquire all outstanding shares of G1 Therapeutics, Inc. for $7.15 per share in cash, implying an approximate equity value of $405 million. The deal brings G1's FDA-approved oncology product COSELA into Pharmacosmos' commercial portfolio to accelerate patient access and expand Pharmacosmos' presence in oncology and supportive care.

Altaris Acquires WuXi AppTec's Advanced Therapies U.S. and U.K. Operations (including OXGENE)

December 24, 2024

Biotechnology

Altaris, a New York-based healthcare-focused investment firm, acquired the U.S. and U.K. operations of WuXi AppTec's Advanced Therapies unit (including OXGENE). Advanced Therapies will be renamed and headquartered in the United States and Altaris intends to combine it with its recently acquired Minaris Regenerative Medicine to form Minaris Advanced Therapies, expanding cell-therapy CDMO capabilities and global footprint.